"We, as well as our commercialization partner, Genzyme are fully committed to bringing DX-88 to HAE patients, and we are confident that the unique attributes of DX-88, including ease of administration and overall clinical profile will allow us to ultimately provide a highly appealing treatment option for HAE patients and their physicians. We will, of course, understand why shareholders might consider us to be a bunch of doofuses, given that we haven't got a handle on optimal dosing. But, hey, they should be used to it by now," said Henry Blair, Chairman and Chief Executive Officer of Dyax.
cgi.peak.org |
